

0/526543

STC 2003/011268 03 MAR 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Kazuhiko IMAKAWA et al. : **Mail Stop: PCT**
Serial No. NEW : Attorney Docket No. 2005_0329A
Filed March 3, 2005 :

REGULATORS FOR IMPLANTATION
[Corresponding to PCT/JP2003/011268
Filed September 3, 2003]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☒ each reference previously cited in the international application PCT/JP2003/011268; and/or
- ☐ each reference previously cited in prior parent application Serial No. _____.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

- 1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) ☐ the certification of paragraph 2 below is provided, **or**
(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

DTOS Rec'd PCT/PTO 0 3 MAR 2005

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☒ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Kazuhiko IMAKAWA et al.

By



Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
March 3, 2005

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: March 3, 2005

ATTY DOCKET NO.
2005_0329AAL NO. **10/526543**
NEWAPPLICANT
Kazuhiko IMAKAWA et al.FILING DATE
March 3, 2005

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AB	01/74841	10/2001	WO			
	AC	98/58962	12/1998	WO			
	AD	98/5323	2/1998	WO			
	AE	94/4670	3/1994	WO			
	AF	00/47228	8/2000	WO			

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AG	K. Nagaoka et al., "Regulation of blastocyst migration, apposition, and initial adhesion by a chemokine, interferon γ -inducible protein 10 kDa (IP-10), during early gestation", The Journal of Biological Chemistry, Vol. 278, No. 31, August 1, 2003, pp. 29048-29056.
	AH	K. Nagaoka et al., "A chemokine, interferon (IFN)- γ -inducible protein 10 kDa, is stimulated by IFN-tau and recruits immune cells in the ovine endometrium", Biol. Reprod., Vol. 68, No. 4, April 2003, pp. 1413-1421.
	AI	N. Imagawa et al., "Ninshin-Chakusho Katei no Kaimei ni Mukete", Japanese Society of Veterinary Science Gakujutsu Shukai Koen Yoshishu, March 25, 2003, Vol. 135 th , page 24, S-S1-6 (in Japanese).
	AJ	N. Nagaoka, et al., "Chakushoki no Hitsuji Shikyunai ni Okeru IFN- γ -inducible protein 10 kDa (IP10) Chemokine no Hatsugen to Sono Kino", Japanese Society of Veterinary Science Gakujutsu Shukai Koen Yoshishu, August 20, 2002, Vol. 134 th , page 73, PL-010 (in Japanese).
	AK	K. Kai et al., "Expression of interferon- γ -inducible protein--10 in human endometrial stromal cells", Mol. Hum. Reprod., Vol. 8, No. 2, February 2002, pp. 176-180.
	AL	A. L. Angiolillo et al., "Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo", J. Exp. Med., Vol. 182, No. 1, 1995, pp. 155-162.
	AM	G. Wood et al., "Relative role of CSF-1, MCP-1/JE, and Rantes in macrophage recruitment during successful pregnancy", Molecular Reproduction and Development, Vol. 46, No. 1, 1997, pp. 62-70.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of form with next communication to applicant.

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: March 3, 2005

ATTY DOCKET NO.
2005_0329AAL NO.
NEW

E01/526543

APPLICANT
Kazuhiko IMAKAWA et al.FILING DATE
March 3, 2005

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BB	97/691	1/1997	WO			
	BC						
	BD						
	BE						
	BF						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	BG	P. Rezaie et al., "Expression of β -chemokines and chemokine receptors in human fetal astrocyte and microglial co-cultures: potential role of chemokines in the developing CNS", GLIA, Vol. 37, No. 1, January 2002, pp. 64-75.
	BH	M. Inngjerdigen et al., "Expression and regulation of chemokine receptors in human natural killer cells", Blood, Vol. 97, No. 2, 2001, pp. 367-375.
	BI	J. M. Farber et al., "Mig and IP-10: CXC chemokines that target lymphocytes", J. Leukoc. Biol., Vol. 61, No. 3, 1997, pp. 246-257.
	BJ	T. Jinqun et al., "CXCR3 expression and activation of eosinophils: role of IFN- γ -inducible protein 10 and monokine induced by IFN- γ ", J. Immunol. Vol. 165, No. 3, 2000, pp. 1548-1556.
	BK	M. Cella et al., "Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon", Nat. Med., Vol. 5, No. 8, 1999, pp. 919-923.
	BL	A. D. Luster et al., " γ -Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins", Nature, Vol. 315, No. 2, 1985, pp. 672-676.
	BM	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of form with next communication to applicant.